Fig. 2: Venous thrombosis-free survival for low and high-risk JAK2V617F positive PV patients from training and validation cohorts stratified by their JAK2V167F VAF (>50% vs ≤50%). | Blood Cancer Journal

Fig. 2: Venous thrombosis-free survival for low and high-risk JAK2V617F positive PV patients from training and validation cohorts stratified by their JAK2V167F VAF (>50% vs ≤50%).

From: JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis

Fig. 2

Kaplan–Meier curves representing venous thrombosis-free survival for training cohort considering those at low risk (A) and high risk (B) at diagnosis. The same analysis on validation cohort patients at low-risk (C) and high-risk (D). The number of patients at risk for each time point is shown below the graph. Tick marks indicate censored data.

Back to article page